Investigational Drug Information for REL-1017
✉ Email this page to a colleague
What is the development status for investigational drug REL-1017?
REL-1017 is an investigational drug.
There have been 9 clinical trials for REL-1017.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2021.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Relmada Therapeutics, Inc., Syneos Health, and Clinical Trial Unit Ente Ospedaliero Cantonale.
There are six hundred and thirty-six US patents protecting this investigational drug and zero international patents.
Summary for REL-1017
| US Patents | 636 |
| International Patents | 12,588 |
| US Patent Applications | 3,083 |
| WIPO Patent Applications | 3,639 |
| Japanese Patent Applications | 55 |
| Clinical Trial Progress | Phase 2 (2021-04-01) |
| Vendors | 6 |
Recent Clinical Trials for REL-1017
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD | Relmada Therapeutics, Inc. | Phase 3 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) | Relmada Therapeutics, Inc. | Phase 3 |
| Open Label Study to Assess the Safety of REL-1017 for Major Depressive Disorder | Relmada Therapeutics, Inc. | Phase 3 |
Clinical Trial Summary for REL-1017
Top disease conditions for REL-1017
Top clinical trial sponsors for REL-1017
US Patents for REL-1017
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| REL-1017 | ⤷ Sign Up | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | ⤷ Sign Up |
| REL-1017 | ⤷ Sign Up | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | Capella Therapeutics, Inc. (San Diego, CA) | ⤷ Sign Up |
| REL-1017 | ⤷ Sign Up | Inhalable pharmaceutical compositions | iCeutica Pty Ltd. (Iluka, WA, AU) | ⤷ Sign Up |
| REL-1017 | ⤷ Sign Up | Powder filling processes | Adamis Pharmaceuticals Corporation (San Diego, CA) | ⤷ Sign Up |
| REL-1017 | ⤷ Sign Up | 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| REL-1017 | ⤷ Sign Up | Compositions and methods for treating cancers | CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) | ⤷ Sign Up |
| REL-1017 | ⤷ Sign Up | Human anti-IL-23 antibodies, compositions, methods and uses | Janssen Biotech, Inc. (Horsham, PA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for REL-1017
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| REL-1017 | Australia | AU2012222348 | 2031-03-01 | ⤷ Sign Up |
| REL-1017 | Australia | AU2012222351 | 2031-03-01 | ⤷ Sign Up |
| REL-1017 | Australia | AU2013224959 | 2031-03-01 | ⤷ Sign Up |
| REL-1017 | Australia | AU2013224960 | 2031-03-01 | ⤷ Sign Up |
| REL-1017 | Australia | AU2014314055 | 2031-03-01 | ⤷ Sign Up |
| REL-1017 | Australia | AU2017210501 | 2031-03-01 | ⤷ Sign Up |
| REL-1017 | Australia | AU2018201400 | 2031-03-01 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
